Liquid Biopsy Preservation Solutions for Standardized Pre-Analytical Workflows-Venous Whole Blood and Plasma

Overview

Journal Curr Pathobiol Rep

Specialty Pathology

Date 2019 Jan 1

PMID 30595972

Citations 39

Authors

Daniel Grolz

Siegfried Hauch

Martin Schlumpberger

Kalle Guenther

Thorsten Voss

Markus Sprenger-Haussels

Uwe Oelmuller

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Liquid biopsy analyses based on circulating cell-free nucleic acids, circulating tumor cells or other diseased cells from organs, and exosomes or other microvesicles in blood offer new means for non-invasive diagnostic applications. The main goal of this review is to explain the importance of preserving whole blood specimens after blood draw for use as liquid biopsies, and to summarize preservation solutions that are currently available.

Recent Findings: Despite the great potential of liquid biopsies for diagnostics and disease management, besides non-invasive prenatal testing (NIPT), only a few liquid biopsy applications are fully implemented for routine in vitro diagnostic testing. One major barrier is the lack of standardized pre-analytical workflows, including the collection of consistent quality blood specimens and the generation of good-quality plasma samples therefrom. Broader use of liquid biopsies in clinical routine applications therefore requires improved pre-analytical procedures to enable high-quality specimens to obtain unbiased analyte profiles (DNA, RNA, proteins, etc.) as they are in the patient's body.

Summary: A growing number of stabilizing reagents and dedicated blood collection tubes are available for the post-collection preservation of circulating cell-free DNA (ccfDNA) profiles in whole blood. In contrast, solutions for the preservation of circulating tumor cells (CTC) that enable both, enumeration and molecular analyses are rare. Solutions for extracellular vesicle (EV) populations, including exosomes, do not yet exist.

Citing Articles

Lessons (to be) learned from liquid biopsies: assessment of circulating cells and cell-free DNA in cancer and pregnancy-acquired microchimerism.

Bergmann L, Afflerbach A, Yuan T, Pantel K, Smit D Semin Immunopathol. 2025; 47(1):14.

PMID: 39893314 PMC: 11787191. DOI: 10.1007/s00281-025-01042-z.

Dynamics and Half-Life of Cell-Free DNA After Exercise: Insights from a Fragment Size-Specific Measurement Approach.

Yamamoto R, Asano H, Tamaki R, Saito Y, Hosokawa A, Watari H Diagnostics (Basel). 2025; 15(1.

PMID: 39795637 PMC: 11720216. DOI: 10.3390/diagnostics15010109.

Establishment of liquid biopsy procedure for the analysis of circulating cell free DNA, exosomes, RNA and proteins in colorectal cancer and adenoma patients.

ceri A, Somborac-Bacura A, Fabijanec M, Hulina-Tomaskovic A, Matusina M, Detel D Sci Rep. 2024; 14(1):26925.

PMID: 39506031 PMC: 11541997. DOI: 10.1038/s41598-024-78497-x.

Standardising the preanalytical reporting of biospecimens to improve reproducibility in extracellular vesicle research - A GEIVEX study.

Lopez-Guerrero J, Vales-Gomez M, Borras F, Falcon-Perez J, Vicent M, Yanez-Mo M J Extracell Biol. 2024; 2(4):e76.

PMID: 38939690 PMC: 11080825. DOI: 10.1002/jex2.76.

The changing face of circulating tumor DNA (ctDNA) profiling: Factors that shape the landscape of methodologies, technologies, and commercialization.

Bronkhorst A, Holdenrieder S Med Genet. 2024; 35(4):201-235.

PMID: 38835739 PMC: 11006350. DOI: 10.1515/medgen-2023-2065.

References

Apostolou P, Ntanovasilis D, Papasotiriou I . Evaluation of a simple method for storage of blood samples that enables isolation of circulating tumor cells 96 h after sample collection. J Biol Res (Thessalon). 2017; 24:11. PMC: 5613324. DOI: 10.1186/s40709-017-0068-9. View

Lee T, Montalvo L, Chrebtow V, Busch M . Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion. 2001; 41(2):276-82. DOI: 10.1046/j.1537-2995.2001.41020276.x. View

Parpart-Li S, Bartlett B, Popoli M, Adleff V, Tucker L, Steinberg R . The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA. Clin Cancer Res. 2016; 23(10):2471-2477. DOI: 10.1158/1078-0432.CCR-16-1691. View

Ayers L, Kohler M, Harrison P, Sargent I, Dragovic R, Schaap M . Measurement of circulating cell-derived microparticles by flow cytometry: sources of variability within the assay. Thromb Res. 2011; 127(4):370-7. DOI: 10.1016/j.thromres.2010.12.014. View

Srinivasan M, Sedmak D, Jewell S . Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol. 2002; 161(6):1961-71. PMC: 1850907. DOI: 10.1016/S0002-9440(10)64472-0. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Jung K, Fleischhacker M, Rabien A . Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature. Clin Chim Acta. 2010; 411(21-22):1611-24. DOI: 10.1016/j.cca.2010.07.032. View

Peters D, Pretorius P . Origin, translocation and destination of extracellular occurring DNA--a new paradigm in genetic behaviour. Clin Chim Acta. 2011; 412(11-12):806-11. DOI: 10.1016/j.cca.2011.01.026. View

Das K, Dumais J, Basiaga S, Krzyzanowski G . Carbon-13 nuclear magnetic resonance analysis of formaldehyde free preservatives. Acta Histochem. 2012; 115(5):481-6. DOI: 10.1016/j.acthis.2012.11.004. View

10.

Lo Y, Chan K, Sun H, Chen E, Jiang P, Lun F . Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med. 2010; 2(61):61ra91. DOI: 10.1126/scitranslmed.3001720. View

11.

Shaw J, Guttery D, Hills A, Fernandez-Garcia D, Page K, Rosales B . Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. Clin Cancer Res. 2016; 23(1):88-96. PMC: 6241844. DOI: 10.1158/1078-0432.CCR-16-0825. View

12.

Gorges T, Kuske A, Rock K, Mauermann O, Muller V, Peine S . Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells. Clin Chem. 2016; 62(11):1504-1515. DOI: 10.1373/clinchem.2016.260299. View

13.

Lui Y, Chik K, Chiu R, Ho C, Lam C, Lo Y . Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem. 2002; 48(3):421-7. View

14.

Nikolaev S, Lemmens L, Koessler T, Blouin J, Nouspikel T . Circulating tumoral DNA: Preanalytical validation and quality control in a diagnostic laboratory. Anal Biochem. 2017; 542:34-39. DOI: 10.1016/j.ab.2017.11.004. View

15.

Kuhlmann J, Wimberger P, Bankfalvi A, Keller T, Scholer S, Aktas B . ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. Clin Chem. 2014; 60(10):1282-9. DOI: 10.1373/clinchem.2014.224808. View

16.

Jiang P, Chan C, Chan K, Cheng S, Wong J, Wong V . Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A. 2015; 112(11):E1317-25. PMC: 4372002. DOI: 10.1073/pnas.1500076112. View

17.

Devonshire A, Whale A, Gutteridge A, Jones G, Cowen S, Foy C . Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem. 2014; 406(26):6499-512. PMC: 4182654. DOI: 10.1007/s00216-014-7835-3. View

18.

Diaz I, Nocon A, Mehnert D, Fredebohm J, Diehl F, Holtrup F . Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing. PLoS One. 2016; 11(11):e0166354. PMC: 5104415. DOI: 10.1371/journal.pone.0166354. View

19.

van Dessel L, Beije N, Helmijr J, Vitale S, Kraan J, Look M . Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions. Mol Oncol. 2017; 11(3):295-304. PMC: 5527445. DOI: 10.1002/1878-0261.12037. View

20.

Allard W, Matera J, Miller M, Repollet M, Connelly M, Rao C . Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20):6897-904. DOI: 10.1158/1078-0432.CCR-04-0378. View